Title of the Research Project: Development of GPCRX allosteric modulators for Van Houten syndrome and other neurological disorders

Name of Principal Researcher (PI): Alison Carlson, MD/PhD

Email: myname@university.edu

Job Title: Associate Professor

Center/Centre: Simpson Center for Drug Discovery

Department: Pharmacology

University/Institution/Company: Springfield University

Phone Number: (800) 000-0000

PI Mailing Address: 1234 Medical Research Building 1
91234 Medical Research Building 3
Springfield, TN, 37232
United States

List of collaborators and/or other partners in the project. Identify support and funding available for the project.
Selma Muntz, Ph.D. (Medicinal Chemist); Nelson Burns, Ph.D. (Molecular Pharmacologist); Manjula Leonard, M.D., Ph.D. (Drug Metabolism Scientist); Andrew McClure, Ph.D. (In vivo and Translational Pharmacology). Project is currently funded by an NIH R01.

A1. Project Name or Drug Target: GPCRx

A2. Therapeutic Areas for Project: Neurological disorders, Rare disease

A3. Therapeutic Area Detail: Van Houten syndrome (VHS, primary), Szyslak syndrome, epilepsy, intellectual disability, schizophrenia, Parkinson's disease

A4. Therapeutic Hypothesis: Primary loss-of-function mutations in the GPCRX gene lead to symptoms that mimic the single-gene disorder VHS, including seizures, intellectual disability, speech difficulties, and gait abnormalities. GPCRx protein levels are also low in autopsy samples of people with VHS and tool compounds that potentiate GPCRx activity can correct abnormal phenotypes in a VHS mouse model. Based on expression of the receptor and its ability to regulate neurotransmitter release, there may also be therapeutic potential in other neurological disorders; these indications are currently being explored in animal models using selective tool ligands.

A5. Genetic evidence for target relevance: Emerging genetic evidence suggests that primary mutations in the GPCRX gene lead to symptoms consistent with VHS.

A6. Pharmacological MOA for target regulation: A GPCRx positive allosteric modulator (PAM) corrects deficits in a VHS mouse model, and we also have evidence for therapeutic potential of GPCRX.
potentiation in mouse models of other rare diseases, such as Szyslak syndrome, as well as multigene disorders, like schizophrenia.

A7. Identify your project type, technology or asset

- Novel assay/technology
- Novel target
- Small molecule program in Hit to Lead Stage

A8. Structural information available for target (e.g. crystal structure)

- Yes

A9. If yes to question A8, describe the structural information available

Insert structural information or reference to structure (e.g., pdb file).

B1. What makes the project novel?

There are no allosteric modulators of GCPRx that have reached the stage of clinical testing.

B2. Risks and potential benefits

Administration of a PAM for one month did not induce overt toxicity in a mouse model of VHS syndrome. As no other compounds have reached clinical development, there is potential to be first-in-class.

B3. Importance of project

No modulators in clinical testing. Genetic evidence suggests a primary link to abnormal phenotypes, but patients are rare. VHS provides an opportunity to test the GPCRx hypothesis in patients with a defined, monogenic disorder. There are no FDA-approved treatments for VHS.

B4. Indicate target population, if known

VHS patients. There are adults with the disorder—propose to start with this population versus pediatric individuals.

B5. Indicate existence of known biomarkers (target engagement assays), if known

We have data with EEG recordings showing an abnormal signature in VHS animals that is corrected with compound. We are also exploring sleep/wake architecture based on signatures seen in Gpcrx KO mice as well as VHS model animals.

B6. Indicate clinical endpoints, if known

Seizures, cognitive endpoints, EEG

C1. Current stage of the project

Hit-2-Lead

C2. Validation of mechanism of action

Early selectivity data showing compounds are selective for target, knockout mice for target available to validate compound activity, knockout mice mimic symptoms of disease

C3. Aim of overall project

Development of GCPRx positive allosteric modulators for Van Houten syndrome

C4. Main approaches to achieve next milestone

Chemical optimization campaign for small molecules

C5. Strengths and experience of team

The Simpson Drug Discovery Center has a well-integrated process for compound development that integrates chemistry, molecular pharmacology, drug metabolism, in vivo studies, and translational biomarker work. For this project, we have completed a high-throughput screen and are currently in hit-to-lead activities. All in vitro and in vivo assays are in place and Springfield University is an ideal environment for VHS research due to the integration of VHS programs within the Simpson Center, the Springfield Taft Center for Intellectual Disability led by clinical VHS expert Dr. Ralph Waylon, and the Springfield Brain Institute led by VHS researcher, Dr. Lisa Bouvier. The Simpson...
Center has now advanced two compounds for other targets/indications into the clinic and is well poised to advance this program into eventual clinical testing.

We have begun a chemical optimization campaign stemming from a successful high throughput screen. We have all of the in vitro pharmacology, drug metabolism, and in vivo pharmacology assays in place to test optimized leads and perform pharmacokinetic/pharmacodynamic associations and are actively working on biomarker strategies.

While this project is in hit-to-lead, we are actively engaged in translational biomarker studies and have found that EEG may have value as a biomarker to assess target engagement and disease modification. We are also working to develop a positron emission tomography ligand for GPCRX to assess receptor occupancy.

Several companies have been reported to be working in this space, but no compounds have been reported to be in trials. Company Y has reported the development of a GPCR agonist, but the current program would focus on PAMs, which is a different mode of pharmacology.

- There is a natural history study of VHS ongoing (clinicaltrials.gov #######)
- A trial with ketamine in VHS is enrolling (clinicaltrials.gov #######)

No patents issued, confidential provisional patent application available under NDA

No; NIH funded

Insert DOI or Pubmed references here

Van Houten syndrome, epilepsy, schizophrenia, Szyslak syndrome, GPCRX, allosteric modulator, high throughput screening, medicinal chemistry, Simpson Center for Drug Discovery, EEG, biomarker